The company provides medical diagnostic services including radiology, pathology, and specialized imaging through a network of retail centers, hospital partnerships, and government contracts.
The business lacks a clear moat as evidenced by stagnant revenue growth and declining EPS over the long term, despite high reported margins. While they claim brand strength in Delhi, the heavy reliance on low-margin government tenders and the commodity nature of pathology suggests limited competitive protection.
Capital has been deployed toward expanding diagnostic centers and servicing government contracts, but the long-term EPS CAGR of -24.2% suggests that these investments have been significantly value-destructive for shareholders despite high ROCE figures.
The business collapsed under the weight of its own receivables as the heavy reliance on government contracts turned into a liquidity trap. While management reported high accounting profits, the cash never arrived, forcing the company to take on expensive debt to fund operations. The commodity nature of the Delhi diagnostic market led to a price war that the company could not win, causing the already negative EPS growth to accelerate downward until the equity value was permanently impaired by a series of dilutive capital raises to stay afloat.
RichFakir rates Star Imaging and Path Lab Ltd's business quality as poor — 45/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Star Imaging and Path Lab Ltd is trading about 43% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Star Imaging and Path Lab Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Star Imaging and Path Lab Ltd's fair value is about ₹127 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →